Azenta (Azenta) Institutional Ownership : 65.12% (As of Apr. 30, 2024)

View and export this data going back to 1995. Start your Free Trial

What is Azenta Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Azenta's institutional ownership is 65.12%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Azenta's Insider Ownership is 10.62%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Azenta's Float Percentage Of Total Shares Outstanding is 72.32%.

Azenta Institutional Ownership Historical Data

The historical data trend for Azenta's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Azenta Institutional Ownership Chart

Azenta Historical Data

The historical data trend for Azenta can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	75.66	74.03	75.75	71.48	68.46	70.44	70.09	67.75	66.70	65.12

Azenta Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Azenta (Azenta) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Azenta Inc (NAS:AZTA) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

BA3:Germany

Address

200 Summit Drive, 6th Floor, Burlington, MA, USA, 01803

Website

https://www.azenta.com

Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.

Executives

Herman Cueto	officer: EVP, Chief Financial Officer	C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
Violetta Hughes	officer: VP, Chief Accounting Officer	C/O AZENTA, INC., 200 SUMMIT DRIVE, 6TH FLOOR, BURLINGTON MA 01803
David C Gray	officer: Chief Strategy & New Business	C/O GT SOLAR INTERNATIONAL, INC., 243 DANIEL WEBSTER HIGHWAY, MERRIMACK NH 03054
Joseph R Martin	director
Dorothy E Puhy	director	DANA FARBER CANCER INSTITUTE, 44 BINNEY STREET, RM. D1632, BOSTON MA 02115
Tina Susan Nova	director	C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Mitchell Coyne	officer: SVP and GM, Life Sciences Proj	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Ginger Zhou	officer: SVP and General Manager, Genom	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Matthew Mcmanus	officer: EVP & Chief Operating Officer	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Lindon G Robertson	officer: EVP & Chief Financial Officer	C/O GRAFTECH INTERNATIONAL LTD., 12900 SNOW ROAD, PARMA OH 44130
Kimberly Crowley	officer: Chief Human Resources Officer	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Vandana Sriram	officer: VP, Finance & Corp. Controller	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Jesus Linda De	officer: Chief Commercial Officer, LS	15 ELIZABETH DRIVE, CHEMSFORD MA 01824
David Jarzynka	officer: Sr. VP, General Manager	15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Robin Vacha	officer: SVP, GM BLS-Products	15 ELIZABETH DRIVE, 15 ELIZABETH DRIVE, CHELMSFORD MA 01824